Extended Data Fig. 4: Inhibition of viral infection and chemokine production by MBL.
From: Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules
(a-c) Inhibition of the infectivity of the D614G (a, b) and B.1.1.7 (α) (c) SARS-CoV-2 variants by MBL in Calu-3 cells. SARS-CoV-2 (a upper panel: MOI = 0.1; b: MOI = 0.1; c: MOI 0.01; a lower panel, MOI = 1) was preincubated in complete medium containing different concentrations of MBL (0.01–10 µg/mL– 0.034-34 nM) before incubation with Calu-3 cells (Virus+MBL) (a), or both virus and cells were pre-incubated with the same concentrations of MBL (Virus+Cells+MBL) (b, c). After 48 and 72 h, the infectivity of SARS-CoV-2 present in cell culture supernatants was determined by a plaque-forming assay in Vero cells. NIL: no MBL. (d) SARS-CoV-2 production at the HBEC apical surface at 72 h PI, in the presence of 25 or 100 µg/ml (75 or 300 nM) PTX3. (e) Chemokine production by SARS-CoV-2 infected HBEC in the presence of MBL. Mean values, n = 2 (a, b, d) or n = 1 (c, e) independent experiments in duplicate cell culture are shown. (a, upper panel) **P = 0.0011, ****P < 0.001; (a, bottom panel) ***P = 1.63 × 10−4, ****P < 0.001; (b) **P = 0.0027, ***P = 1.35 × 10−4, ****P < 0.001; (c) **P = 0.0024, ***P = 8.32 × 10−4 Statistical analysis was determined by two-way (a, b, c, e) or one-way (d) ANOVA, followed by Bonferroni’s multiple comparison test.
